Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

18.20 +0.04 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,455,500
Open 18.09
Bid (Size) 16.10 (1)
Ask (Size) 19.00 (1)
Prev. Close 18.16
Today's Range 18.06 - 18.55
52wk Range 17.48 - 52.44
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
Exposures Product Safety
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-45.1%
-45.1%
1 Month
-25.4%
-25.4%
3 Month
-38.8%
-38.8%
6 Month
-34.8%
-34.8%
1 Year
-62.1%
-62.1%

More News

Read More
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
Via Benzinga
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Via Benzinga
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views
Via Benzinga
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
Analyst Expectations For Apellis Pharmaceuticals's Future
Via Benzinga
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For February 28, 2025
Via Benzinga
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
Via Benzinga
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Via Benzinga
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Keli Walbert to Join the Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 18.20
When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 04/17/25 04:00 PM ET
What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 2.12B
How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
Apellis Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.